Washirasaksiri C.Sayabovorn N.Ariyakunaphan P.Kositamongkol C.Chaisathaphol T.Sitasuwan T.Tinmanee R.Auesomwang C.Nimitpunya P.Woradetsittichai D.Chayakulkeeree M.Phoompoung P.Mayurasakorn K.Sookrung N.Tungtrongchitr A.Wanitphakdeedecha R.Muangman S.Senawong S.Tangjittipokin W.Sanpawitayakul G.Nopmaneejumruslers C.Vamvanij V.Phisalprapa P.Srivanichakorn W.Mahidol University2023-09-102023-09-102023-12-01Scientific Reports Vol.13 No.1 (2023)https://repository.li.mahidol.ac.th/handle/20.500.14594/89620Few studies have identified the metabolic consequences of the post-acute phase of nonsevere COVID-19. This prospective study examined metabolic outcomes and associated factors in nonsevere, RT-PCR-confirmed COVID-19. The participants’ metabolic parameters, the prevalence of long-term multiple metabolic abnormalities (≥ 2 components), and factors influencing the prevalence were assessed at 1, 3, and 6 months post-onset. Six hundred individuals (mean age 45.5 ± 14.5 years, 61.7% female, 38% high-risk individuals) with nonsevere COVID-19 attended at least one follow-up visit. The prevalence of worsening metabolic abnormalities was 26.0% for BMI, 43.2% for glucose, 40.5% for LDL-c, 19.1% for liver, and 14.8% for C-reactive protein. Except for lipids, metabolic-component abnormalities were more prevalent in high-risk hosts than in healthy individuals. The prevalence of multiple metabolic abnormalities at the 6-month follow-up was 41.3% and significantly higher in high-risk than healthy hosts (49.2% vs 36.5%; P = 0.007). Factors independently associated with a lower risk of these abnormalities were being female, having dyslipidemia, and receiving at least 3 doses of the COVID-19 vaccine. These findings suggest that multiple metabolic abnormalities are the long-term consequences of COVID-19. For both high-risk and healthy individuals with nonsevere COVID-19, healthcare providers should monitor metabolic profiles, encourage healthy behaviors, and ensure complete vaccination.MultidisciplinaryLong-term multiple metabolic abnormalities among healthy and high-risk people following nonsevere COVID-19ArticleSCOPUS10.1038/s41598-023-41523-52-s2.0-851694042992045232237653091